Search PubMed⌕ Search

Biomedical subjects

T Sakiyama

Publications and source records attributed to T Sakiyama.

87 records · Page 5Linked to original sources
PubMed1980

Synthesis of first trimester placental alkaline phosphatase in cultured human term placental cells.

Alkaline phosphatase activity in human placental cells transformed by a tsA mutant of simian virus 40 (SV40) can be greatly induced by growing these cells at 40 degrees C, the temperature at which the tsA transformants regain their nontransformed phenotype. The induction of alkaline phosphatase in these cells requires the synthesis of both RNA and protein. The induced alkaline phosphatase from a SV40 tsA30 mutant-transformed term placental cell line (TPA30-1) was purified, characterized, and compared with alkaline phosphatase from term placenta and first trimester placenta. The form of alkaline phosphatase found in TPA30-1 cells differs from the phosphatase of term placenta in physiochemical and immunological properties. The TPA30-1 phosphatase is, however, indistinguishable from the alkaline phosphatase of human first trimester placenta by several criteria, including electrophoretic mobility, apparent molecular weight (Mr = 165,000), size of monomeric subunit (Mr = 77,000), heat lability, and sensitivity to inhibition by amino acids and EDTA. In addition, alkaline phosphatase from both TPA30-1 cells and first trimester placenta can be inactivated by antiserum to liver alkaline phosphatase but not by antiserum to term placental alkaline phosphatase. The induction of first trimester phosphatase in cells derived from term placenta provides a system for the study of alkaline phosphatase gene regulation in human placenta.

Alkaline Phosphatase↗
PubMed1980

Prenatal diagnosis of I-cell disease by measuring altered alpha-mannosidase activity in amniotic fluid.

Prenatal diagnoses of I-cell disease were carried out by examination of the amniotic fluid and cultured amniotic cells in four cases of high-risk pregnancy in three different families. Three of the four fetuses were diagnosed as having I-cell disease, on the basis of observation of abnormally increased activity of lysosomal acid hydrolases in the amniotic fluid and their decreased activity in cultured amniotic cells, thus leading to therapeutic abortion. alpha-Mannosidase in the amniotic fluid of the fetuses with I-cell disease exhibited significant alterations in pH profile Km value, thermal stability and isoelectric focusing pattern, compared with the enzyme in normal controls. The results indicate that prenatal diagnosis of I-cell disease may be accomplished by demonstration of altered enzymological characteristics of alpha-mannosidase in the supernatant of amniotic fluid. The significance of the alteration of alpha-mannosidase in the amniotic fluid is not known.

Amniotic Fluid↗
PubMed1979

Characterization of alkaline phosphatases from human first trimester placentas.

Alkaline phosphatase from human first trimester placentas was purified, characterized, and compared with alkaline phosphatases from term placenta and liver. Three forms of first trimester placental alkaline phosphatase (I, IIa, and IIb) were isolated; their relative amounts were 35%, 39%, and 26%, respectively. Phosphatases I and IIa were found to be dimers, whereas phosphatase IIb appeared to be a tetramer consisting of two dimers of phosphatase I or IIa. Phosphatase I was indistinguishable from liver phosphatase by several criteria including apparent molecular weight (Mr = 165,000), size of the monomeric subunit (Mr = 77,000), heat liability, insensitivity to inactivation by antiserum against term placental alkaline phosphatase, and sensitivity to inactivation by antiserum against liver alkaline phosphatase. In addition, phosphatase I and liver phosphatase were equally sensitive to inhibition by amino acids, levamisole, l-p-bromotetramisole, and EDTA. Phosphatase IIa, in contrast, was indistinguishable from term placental alkaline phosphatase by the same criteria: apparent molecular weight (Mr = 115,000), size of the monomeric subunit (Mr = 63,000), heat stability, inactivation by antiserum against term placental alkaline phosphatase, and sensitivity to inhibition by various compounds. These findings clearly demonstrate the existence of two distinct placental alkaline phosphatases, one (phosphatase I) specific for the first trimester placenta and the other (phosphatase IIa) occurring in both first trimester and term placentas.

Alkaline Phosphatase↗
PubMed1978

In utero diagnosis of Gaucher disease.

Beta-Glucosidase activity measured by synthetic substrate at pH 4.6 was low in the cultured amniotic cells from two pregnant women at risk for juvenile and adult type Gaucher disease. The diagnosis was confirmed by showing a low activity of beta-glucosidase in the skin fibroblasts with a synthetic substrate or in the spleen with a natural substrate, and by ascertaining the presence of Gaucher cells in the fetal tissues. However, considerable activity of beta-glucosidase measured with synthetic substrate was found in the liver of both affected fetuses and in the spleen of one. It is advisable that the determination of beta-glucosidase to confirm prenatal diagnosis of Gaucher disease be done either in the cultured skin fibroblasts or in the spleen, and if in the spleen, with a natural substrate rather than a synthetic one.

Amniocentesis↗
PubMed1977

Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver.

beta-Glucosidase activity was measured in control subjects and in five patients with neuropathic Gaucher's disease. In three patients with Gaucher's disease, methylumbelliferyl- and p-nitrophenyl-beta-d-glucopyranoside (4MU- and PNP-beta-glucosidase) activity was almost normal in the liver but markedly reduced in the spleen and fibroblasts. In the other patients with Gaucher's disease 4MU- and PNP-beta-glucosidase activity was also very much reduced in the liver, spleen, and fibroblasts. DEAE-cellulose column chromatography with a chloride gradient elution of the liver extract from a control subject and from two patients with Gaucher's disease, exhibiting normal 4MU- and PNP-beta-glucosidase activity, revealed the presence of two peaks of 4MU- and PNP-beta-glucosidase activity (fractions 1 and 2). pH activity curves of beta-glucosidases and Km measured with 4MU-beta-glucoside in fractions 1 and 2 from patients with Gaucher's liver were identical to those from the control liver. However, fractions 1 and 2 from infantile Gaucher's liver exhibited no activity measured with glucocerebroside whereas those from juvenile Gaucher's liver showed a considerable activity. Glucocerebroside was greatly accumulated in the liver, even though an almost normal activity of 4MU-beta-glucosidase was detected in three of the five patients studied.

Cerebrosides↗
PubMedDate not supplied

Sphingomyelinosis, a new mutation in the mouse: a model of Niemann-Pick disease in humans.

A new autosomal recessive gene causing sphingomyelinosis in mice is described. The name sphingomyelinosis is proposed for this mutant with the gene symbol spm. The disease syndrome caused by this gene has been diagnosed as an analogue of Niemann-Pick disease in humans. Affected mice cannot breed. They show neurological symptoms and weight loss beginning from around 7 weeks of age, and die at 12-14 weeks. By 8 weeks of age striking hepatosplenomegaly and marked enlargement of lymph nodes are present. Large areas of the liver and spleen are replaced by clusters of foam cells. Purkinje cells in the cerebellum are severely depleted. The contents of sphingomyelin and free cholesterol in the liver and spleen are markedly elevated. But the brain shows no obvious changes in lipid concentrations. Sphingomyelinase activity is reduced to about 30 percent that of the homozygous normal controls in the liver, 50 percent in the spleen and 70-80 percent in the brain. Heterozygotes are normal in both lipid concentrations and sphingomyelinase activity. The syndrome produced by spm is different in several ways from that produced by fm, which has been reported to cause sphingomyelinosis in mice.

Animals↗
PubMedDate not supplied

Time course of hepatic lipids accumulation in a strain of mice with an inherited deficiency of sphingomyelinase.

Sphingomyelinosis (gene symbol, spm) is a recessive autosomal mutation in mice that causes a condition analogous to the human disease known as Niemann-Pick disease. The time course of hepatic lipids accumulation in this murine model was investigated. Hepatosplenomegaly in spm/ spm mice was noticeable as early as 4 weeks of age, and reached its maximum level at 6 weeks of age. Thereafter the weights of liver and spleen decreased in parallel with a decrease in body weight and an increase in severity of neurological symptoms. Hepatic concentrations of unesterified cholesterol and sphingomyelin were considerably elevated by 4 weeks of age, and further increased linearly to the terminal stages of the disorder. Sphingomyelinase activities in the livers of spm/ + and +/+ mice showed normal adult levels from as early as 4 weeks of age, whereas the activity in spm/ spm mice was consistently 30-40 percent of the normal level from 4 to 12 weeks of age.

Age Factors↗